FINANCIAL EXPRESS



Coal India Limited

A Maharatna Company (A Govt. of India Enterprise) 3rd Floor, Core-2, Premises No. 04-MAR, Plot No. AF-III, Action Area-1A, Newtown, Rajarhat, Kolkata-700156 Phone: 033-2324-6526, Fax: 033-23246510 E-mail: mviswanathan2.cil@coalindia.in Website: www.coalindia.in CIN- L23109WB1973GOI028844

NOTICE FOR BOARD MEETING

Pursuant to Regulation 29 & 33 of the Listing Regulations 2015, notice is hereby given that a meeting of Board of Directors of the company will be held on Thursday, the 11th February, 2021 inter-alia to consider, approve and take on record Un-Audited Financial Results of the Company (Standalone & Consolidated) for the 3rd quarter ended 31st December, 2020.

The Company has already closed its "Trading Window" under "CODE OF INTERNAL PROCEDURES AND CONDUCT FOR PREVENTION OF INSIDER TRADING IN SECURITIES OF COAL INDIA LIMITED" from 28th December, 2020 and it will re-open on 16th February, 2021.

The said notice may be accessed on the company's website at www.coalindia.in under "Investor Center, Events & Announcements" and also on Stock Exchange websites www.bseindia.com and www.nseindia.com For Coal India Limited

Place : Kolkata (M. Viswanathan) Company Secretary & Compliance Office Date: 27th January, 2021

FEDERAL BANK

THE FEDERAL BANK LTD. REG. OFFICE: PB. No: 103, FEDERAL TOWERS, ALUVA, KERALA, INDIA - 683 101 Phone: 0484-2622263, E-MAIL: secretarial@federalbank.co.in, Website: www.federalbank.co.in, CIN: L65191KL1931PLC000368

NOTICE

Notice is hereby given that the following share certificates have been reported lost. The Bank will proceed to issue duplicate certificates in respect of these shares if no valid objection is received within 15 days from the date of publication of this notice.

.NO. SHH	DIST.NO.	CERT.NO.	FOLIO	(DUP. APPLIED BY)	NO.
	1705403808- 1705407807	603363	22538	MATHAIVT	1

Samir P Raidev Company Secretary 29.01.2021

DB Corp Ltd

Extract of Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2020

NAME

(₹ in million except per share data)

	Consolidated			
Particulars	Dec 31, 2020	Dec 31, 2019	Dec 31, 2020	
	Qtr (Unaudited)	Qtr (Unaudited)	YTD (Unaudited)	
Total income from operations	4,943.21	5,987.49	10,511.01	
Net profit/ (loss) for the period (before tax, exceptional and/or extraordinary items)	1,332.91	1,084.13	1,083.45	
Net profit/ (loss) for the period before tax (after exceptional and/or extraordinary items)	1,332.91	1,084.13	1,083.45	
Net profit/ (loss) for the period after tax (after exceptional and/or extraordinary items)	990.36	816.26	795.10	
Total comprehensive income/ (loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income / (loss) (after tax)]	990.36	816.26	793.98	
Paid-up equity share capital (face value Rs. 10/- each, fully paid)	1,749.55	1,749.47	1,749.55	
Earning Per Share (of Rs. 10/- each)				
- Basic	5.66	4.67	4.54	
- Diluted	5.65	4.66	4.53	
) The above results have been reviewed by the Audit Committee and approved by the f	Board of Directors	at their respective	meetings held or	

January 28, 2021. There are no qualifications in the report issued by the auditors.

2) Unaudited Financial Results for the guarter and nine months ended December 31, 2020 (on Standalone basis):

(₹ in million)

	Particulars	Dec 31, 2020	Dec 31, 2019	Dec 31, 2020
	rai ticulai s	Qtr (Unaudited)	Qtr (Unaudited)	YTD (Unaudited)
	Total income from operations	4,943.21	5,986.39	10,511.01
	Profit / (loss) before tax for the period	1,332.89	1,083.19	1,083.33
	Profit / (loss) after tax for the period	990.34	815.32	794.97
1	2) Upportainty agus ad by the Covid 10 pandamic has lad to the short term slowdown in the	business energiar	howover the Gr	oun ic ovnorionoina

3) Uncertainty caused by the Covid-19 pandemic has led to the short-term slowdown in the business operations, however the Group is experiencing pick-up of its operations post lock down. Based on internal and external information available at the date of approval of these financial results, the Group has considered the possible effects that may result from COVID-19, and based on detailed assessment, the Group expects to recover the carrying amount of its financial and non-financial assets. The impact of COVID-19 on the financial results may differ from that estimated as at the date of approval of these financial results.

4) The above is an extract of the detailed format of Unaudited Standalone and Consolidated Financial Results for the guarter and nine months ended December 31, 2020 filed with the Stock Exchanges under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results is available on the websites of the Stock Exchanges www.bseindia.com, www.nseindia.com and on Company's website www.dbcorpltd.com.

For and on behalf of the Board of Directors

Place: Bhopal **Date: January 28, 2021**

Sudhir Agarwal Managing Director (DIN: 00051407)

Nine Months | Nine Months

Ended

Ended

D. B. Corp Ltd. - Registered Office: Plot No.280, Sarkhej - Gandhinagar Highway, Near YMCA Club, Makarba, Ahmedabad - 380051, Gujarat Email: dbcs@dbcorp.in • Website: www.dbcorpltd.com • Tel No.: 022 - 71577000 • CIN No: L22210GJ1995PLC047208

COLGATE-PALMOLIVE (INDIA) LIMITED

Registered Office: Colgate Research Centre, Main Street, Hiranandani Gardens, Powai, Mumbai 400 076 CIN: L24200MH1937PLC002700 Tel: +91 (22) 6709 5050 Fax: +91 (22) 2570 5088 Email ID: investors grievance@colpal.com Website: www.colgatepalmolive.co.in

Ended

STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

Ended

Ended

(Rs. in Lakhs)

Ended

	Particulars	December 31,	September 30, 2020	December 31,	2020	December 31, 2019	March 31, 2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income	o de			8		
	(a) Revenue from operations						
	(i) Sales (Refer Note 1)	122,421	127,766	113,602	353,547	342,522	448,757
	(ii) Other Operating Income	772	782	1,115	2,256	2,861	3,752
	(b) Other Income	988	757	580	2,373	2,960	4,924
	Total Income	124,181	129,305	115,297	358,176	348,343	457,433
2	Expenses						
	(a) Cost of materials consumed	31,731	36,571	36,595	92,527	102,921	135,033
	(b) Purchases of stock-in-trade	6,482	10,383	6,465	25,131	18,527	24,411
	(c) Changes in inventories of finished goods,						
	work-in-progress and stock-in-trade	(960)	(5,991)	(3,748)	(4,206)	(2,022)	(2,156)
	(d) Employee benefits expense	8,688	9,660	7,704	27,416	24,239	33,228
	(e) Finance Cost	189	182	292	570	764	962
	(f) Depreciation and Amortisation expense	4,556	4,611	5,150	13,705	15,177	19,794
	(g) Other Expenses						
	(i) Advertising	19,830	16,441	14,339	47,664	47,052	62,602
	(ii) Others	20,361	20,555	21,757	58,483	60,784	79,222
	Total Expenses	90,877	92,412	88,554	261,290	267,442	353,096
3	Profit Before Tax (1-2)	33,304	36,893	26,743	96,886	80,901	104,337
4	Tax expense (Refer Note 2)						
	i) Current Tax	8,772	9,456	6,969	25,661	21,474	24,750
	ii) Deferred Tax	(304)	18	(136)	(848)	(1,805)	(2,060)
5	Net Profit for the period/year (3-4)	24,836	27,419	19,910	72,073	61,232	81,647
6	Other Comprehensive Income (net of Tax)						
	Items that will not be reclassified to Profit and Loss						
	i) Re-measurement (losses) on defined benefit plans	-	-	-	_	-	(2,075)
	ii) Tax adjustment on above	-	-	-	_	-	522
7	Total comprehensive income for the period/year (5+6	24,836	27,419	19,910	72,073	61,232	80,094
8	Paid-up Equity Share Capital						
	(Face value: Re 1/- per share)	2,720	2,720	2,720	2,720	2,720	2,720
9	Reserve excluding Revaluation Reserve						
10							156,696
	each) (not annualised)	9.13	10.08	7.32	26.50	22.51	30.02
No	, ,	i v			l V	1	Y)

- 1. Sales, net of GST, for the quarter ended and nine months ended December 31, 2020 increased by 7.8% and 3.2% respectively in comparison to the corresponding period of the previous year.
- 2. Tax expense for the year ended March 31, 2020 is net of prior year reversal of Rs. 3,099 Lakhs, whereas prior year reversals are 'Nil' for the guarter and nine months ended December 31, 2020 and December 31, 2019.
- 3. The Code on Social Security 2020 has been notified in the Official Gazette on 29th September 2020, which may impact the contributions by the Company towards certain employment benefits. The effective date from which the changes are applicable is vet to be notified, and the rules are vet to be framed. Impact if any of the changes will be assessed and accounted for in the period of notification of the relevant provisions.
- 4. The Company has identified 'Personal Care (including Oral Care)' as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no separate segment information has been provided. 5. Previous period/year figures have been reclassified, as considered necessary, to conform with current period/year presentation,
- where applicable. 6. The Statutory Auditors have carried out a Limited Review of the Financial results for the guarter and nine months ended December
 - 31, 2020 as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 28, 2021.

The full text of Colgate releases is available in the Investors section of our website at www.colgatepalmolive.co.in and is also available on www.bseindia.com and www.nseindia.com.

COLGATE-PALMOLIVE (INDIA) LIMITED

MANAGING DIRECTOR

(M) IDBI BANK

IDBI BANK LIMITED

CIN: L65190MH2004GOI148838

Regd. Office: IDBI Tower, WTC Complex, Cuffe Parade, Mumbai - 400005,

Tel.: (022) 66552779 / 66553336 Fax: (022) 2218 2352, website: www.idbibank.in, email id: idbiequity@idbi.co.in

			Standalone			Consolidated		
SI. No.	Particulars	Quarter ended 31-12-2020 (Reviewed)	Nine Months ended 31-12-2020 (Reviewed)	Quarter ended 31-12-2019 (Reviewed)	Quarter ended 31-12-2020 (Reviewed)	Nine Months ended 31-12-2020 (Reviewed)	Quarter ended 31-12-2019 (Reviewed)	
1	Total Income from Operations (net)	5932.25	17594.34	6215.60	5987.86	17751.45	6267.23	
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	842,95	1945,98	755,89	869.92	2017.64	778.43	
3	Net Profit /(Loss) for the period before tax (after Exceptional and / or Extraordinary items)	842.95	1945.98	755.89	869.92	2017.64	778.43	
4	Net Proft / (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	378.42	847.26	(5763.04)	393.15	884.92	(5728.70)	
5	Equity Share Capital	10752.40	10752.40	10380.59	10752.40	10752.40	10380.59	
6	Reserves(excluding Revaluation Reserve as shown in the Audited Balance Sheet of the previous year)	17140.41	17140.41	23147.71	17951.76	17951.76	23882.72	
7	Earnings Per Share (of Rs. 10/- each) in Rs. (for continuing and discontinued operations before & after extraordinary items) (not annualised)							
	Basic	0.36	0.81	(5.91)	0.38	0.85	(5.88)	
	Diluted	0.36	0.81	(5.91)	0.38	0.85	(5.88)	

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED DECEMBER 31, 2020

Notes: 1 The above is an extract of the detailed format of Quarterly/Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Nine Monthly Financial Results are available on the websites of the Stock Exchange (s) and the listed entity, websites (www.nseindia.com,www.bseindia.com and www.idbibank.in).

2 Information relating to Total Comprehensive Income and Other Comprehensive Income are not furnished as Ind AS is not yet made applicable to banks.

By order of the Board

Place: Mumbai Date : January 28, 2021

(Suresh Khatanhar) **Deputy Managing Director**

(J. Samuel Joseph) **Deputy Managing Director**

(Rakesh Sharma) Managing Director & CEO

Adfactors 807

Evis **ERIS LIFESCIENCES LIMITED**

Regd. Office: 8th Floor, Commerce House- IV, Prahladnagar, Ahmedabad - 380015 Email: complianceofficer@erislifesciences.com Website: www.eris.co.in Tel: +91 79 3045 1000 Fax: +91 79 3017 9404 CIN: L24232GJ2007PLC049867

EXTRACT OF CONSOLIDATED FINANCIAL RESULTS

FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

[Rs. in Million except per share data] For Quarter For Quarter For Nine For Nine For Year

Particulars	Ended (Unaudited)	Ended (Unaudited)	Ended (Unaudited)	months Ended (Unaudited)	months Ended (Unaudited)	Ended (Audited)
	December 31, 2020	September 30, 2020	December 31, 2019	December 31, 2020	December 31, 2019	March 31, 2020
Revenue from Operations	3,104.23	3,299.92	2,663.99	9,336.57	8,254.93	10,740.59
Net Profit for the period before tax and exceptional items	992.96	1,158.36	721.60	3,097.69	2,698.54	3,313.50
Net Profit for the period before tax and after exceptional items	992.96	1,158.36	721.60	3,097.69	2,698.54	3,313.50
Net Profit for the period after tax	901.50	1,077.20	634.69	2,868.88	2,402.35	2,965.07
Total Comprehensive Income for the period after tax	900.08	1,065.12	633.95	2,853.96	2,397.01	2,952.89
Equity Share Capital (Face Value of Rs. 1/- each)	135.78	135.78	137.52	135.78	137.52	135.78
Other Equity	NA	NA	NA	NA	NA	12,827.56
Earnings Per Share (of Rs.1/- each) (not annualised):			6			
Basic	6.64	7.93	4.62	21.13	17.47	21.61
Diluted	6.63	7.93	4.61	21.11	17.45	21.59

1 Summary of standalone financial results of Eris Lifesciences Limited :

IDe is Milliani

Particulars	Ended	For Quarter Ended (Unaudited)	Ended (Unaudited)	For Nine months Ended (Unaudited) (For Nine months Ended (Unaudited)	For Year Ended (Audited)
	December 31, 2020	September 30, 2020	December 31, 2019	December 31, 2020	December 31, 2019	March 31, 2020
Revenue from Operations	2,871.31	3,033.73	2,542.69	8,519.85	7,894.94	10,202.31
Profit before tax	973.71	1,129.36	710.06	3,024.63	2,643.77	3,235.92
Profit after tax	886.34	1,054.92	626.76	2,812.57	2,361.67	2,912.74
Total Comprehensive Income (after tax)	885.03	1,042.96	626.11	2,798.00	2,356.62	2,901.03

2 The above is an extract of the detailed format of quarterly financial results filed with the stock exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the stock exchanges websites (www.nseindia.com and www.bseindia.com) and on the company's website www.eris.co.in. 3 The above results were reviewed by the Audit Committee and approved by the Board at their meeting held on January 28, 2021. The same have

also been subjected to Limited Review by the Statutory Auditors. For Eris Lifesciences Limited

Place: Ahmedabad Date : January 28, 2021

Adfactors 838

(₹ in Crore)







HSIL Limited Regd. Office: 2, Red Cross Place, Kolkata-700 001, Tel: 033-22487407/5668



SOMANY IMPRESA GROUP COMPANY

Chairman and Managing Director

Website: www.hsilgroup.com | Email: hsilinvestors@hsilgroup.com | CIN: L51433WB1960PLC024539

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 31 DECEMBER 2020

Sr. No.	Particulars	3 months ended 31 December 2020 (Unaudited)	Year to date figures for current period ended 31 December 2020 (Unaudited)	Corresponding 3 months ended 31 December 2019 in the previous year (Unaudited)	Year ended 31 March 2020 (Audited)
1	Total income from operations	547.59	1242.33	494.19	1879.37
2	Net profit from ordinary activities before tax	51.08	58.13	24.51	75.00
3	Net profit from ordinary activities after tax	35.92	55.04	15.70	48.42
4	Net profit for the period after tax (after extraordinary items)	35.92	55.04	15.70	48.42
5	Other comprehensive income / (expenditure) (net of tax)	(0.15)	(0.46)	(0.16)	(7.49)
6	Total comprehensive income	35.77	54.58	15.54	40.93
7	Equity share capital	12.94	12.94	14.46	14.46
8	Reserves (excluding revaluation reserve/business reconstruction reserve) as shown in the audited balance Sheet of the previous year	(2)		1.51	964.65
9	Earning per share (before extraordinary items) (of ₹ 2/- each) (not annualized) (a) Basic (₹) (b) Diluted (₹)	5.08 5.08	7.78 7.78	2.17 2.17	6.69 6.69
10	Earning per share (after extraordinary items) (of ₹ 2/- each) (not annualized) (a) Basic (₹) (b) Diluted (₹)	5.08 5.08	7.78 7.78	2.17 2.17	6.69 6.69

(1) The Audit Committee has reviewed these results and the Board of Directors has approved the above results and its release at their respective meetings held on

28 January, 2021. The statutory auditors of the Company have also carried out the limited review of the above results. (2) The above is an extract of the detailed format of the financial result for the quarter and period ended 31 December 2020 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results for the quarter and period ended 31 December 2020. is available on the websites of Stock Exchanges (www.bseindia.com and www.nseindia.com) and on the Company's website "www.hsilgroup.com"

> Sandip Somany Vice Chairman and Managing Director



RAM RAGHAVAN

Date: 28 January 2021

Place : Gurugram

financialexp.epa

Place: Mumbai

Date: January 28, 2021